Form 4: Avid Bioservices Director Joseph Carleone Reports Stock Transactions

Director Joseph Carleone of Avid Bioservices, Inc. reports the vesting of restricted stock units and a new equity award grant.

Summary

• Joseph Carleone, a director at Avid Bioservices, Inc., reported transactions involving the company's stock.
• On December 14, 2024, 26,756 restricted stock units (RSUs) vested, converting into common stock.
• Also on December 14, 2024, Carleone received an annual equity award grant of 8,147 RSUs.
• The vested RSUs were granted on December 14, 2023, and the new grant will vest on December 14, 2025, subject to continued service.
• Following these transactions, Carleone directly owns 8,147 RSUs.

Sentiment

Score: 7

Explanation: The document reflects standard compensation practices and does not indicate any significant positive or negative events. The vesting of RSUs is a positive for the director, but it is an expected event.

Positives

• The vesting of RSUs indicates that performance conditions were met for the previous grant.
• The new equity award grant aligns the director's interests with the company's long-term performance.

Risks

• The vesting of a large number of shares could potentially increase selling pressure on the stock if the director chooses to sell.
• The future vesting of the new RSU grant is contingent on the director's continued service, which introduces a risk of forfeiture if service is terminated.

Future Outlook

The 8,147 RSUs granted on December 14, 2024, will vest on December 14, 2025, subject to the director's continued service.

Industry Context

This filing is a routine disclosure of stock transactions by a company director, which is common in publicly traded companies. It reflects standard compensation practices for board members.

Comparison to Industry Standards

• Equity compensation, such as RSUs, is a common practice for directors in the biotechnology and pharmaceutical industries, similar to companies like Catalent and Lonza.
• The vesting schedule of one year for the initial grant and another year for the new grant is typical for director equity awards.
• The number of RSUs granted is within the range of what is seen for non-executive directors in comparable companies.

Stakeholder Impact

• The vesting of RSUs and the new grant align the director's interests with those of shareholders.
• The transactions have a minor impact on the total number of shares outstanding.

Next Steps

• The director will continue to serve on the board, and the new RSUs will vest on December 14, 2025, if service continues.

Key Dates

Keywords

Avid Bioservices, Director, Joseph Carleone, Restricted Stock Units, RSU, Stock Vesting, Equity Award, SEC Form 4, Beneficial Ownership